Key Points
- Blake Borgeson, a director at Recursion Pharmaceuticals (RXRX), sold 220,000 shares on Feb. 3 at an average price of $4.20 for about $924,000, cutting his ownership by 3.31% to 6,429,863 shares valued at roughly $27.0M.
- Borgeson made two prior identical sales—220,000 shares on Jan. 6 at $4.36 and 220,000 on Dec. 2 at $4.37—bringing the three-sale total to 660,000 shares for approximately $2,844,600.
- Recursion's fundamentals remain challenged (negative EPS, revenue down ~80% YoY), a market cap near $2.07B, and analysts hold a consensus "Hold" with an average price target of $9.40 (several firms target $11, one reissued a "sell").
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) Director Blake Borgeson sold 220,000 shares of the stock in a transaction on Tuesday, February 3rd. The stock was sold at an average price of $4.20, for a total value of $924,000.00. Following the transaction, the director owned 6,429,863 shares of the company's stock, valued at approximately $27,005,424.60. This represents a 3.31% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.
Blake Borgeson also recently made the following trade(s):
- On Tuesday, January 6th, Blake Borgeson sold 220,000 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $4.36, for a total transaction of $959,200.00.
- On Tuesday, December 2nd, Blake Borgeson sold 220,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $4.37, for a total transaction of $961,400.00.
Recursion Pharmaceuticals Stock Performance
Shares of RXRX stock opened at $3.98 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.60 and a current ratio of 4.60. The firm has a market cap of $2.07 billion, a P/E ratio of -2.21 and a beta of 0.95. The firm's 50 day moving average price is $4.45 and its 200-day moving average price is $4.94. Recursion Pharmaceuticals, Inc. has a one year low of $3.54 and a one year high of $12.36.
Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last posted its earnings results on Wednesday, November 5th. The company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.38) by $0.02. The firm had revenue of $5.18 million during the quarter, compared to the consensus estimate of $19.36 million. Recursion Pharmaceuticals had a negative net margin of 1,637.81% and a negative return on equity of 72.74%. The firm's revenue for the quarter was down 80.1% on a year-over-year basis. During the same quarter last year, the firm earned ($0.34) EPS. As a group, equities research analysts predict that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.
Analyst Upgrades and Downgrades
RXRX has been the subject of a number of research analyst reports. JPMorgan Chase & Co. upgraded Recursion Pharmaceuticals from a "neutral" rating to an "overweight" rating and raised their target price for the company from $10.00 to $11.00 in a report on Wednesday, December 17th. UBS Group set a $11.00 price target on shares of Recursion Pharmaceuticals in a research report on Wednesday, December 17th. Weiss Ratings reissued a "sell (d-)" rating on shares of Recursion Pharmaceuticals in a research note on Thursday, January 22nd. Finally, Morgan Stanley set a $11.00 target price on shares of Recursion Pharmaceuticals in a research note on Wednesday, December 17th. Two equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $9.40.
Check Out Our Latest Research Report on RXRX
Hedge Funds Weigh In On Recursion Pharmaceuticals
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Brighton Jones LLC raised its holdings in Recursion Pharmaceuticals by 49.4% in the fourth quarter. Brighton Jones LLC now owns 20,261 shares of the company's stock valued at $137,000 after acquiring an additional 6,699 shares in the last quarter. Royal Bank of Canada increased its position in shares of Recursion Pharmaceuticals by 627.6% in the 1st quarter. Royal Bank of Canada now owns 269,013 shares of the company's stock valued at $1,423,000 after purchasing an additional 232,038 shares during the last quarter. AQR Capital Management LLC acquired a new stake in shares of Recursion Pharmaceuticals in the 1st quarter valued at $890,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Recursion Pharmaceuticals by 7.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 177,434 shares of the company's stock worth $953,000 after purchasing an additional 12,372 shares during the last quarter. Finally, Focus Partners Wealth acquired a new position in shares of Recursion Pharmaceuticals during the first quarter worth $77,000. 89.06% of the stock is owned by institutional investors and hedge funds.
About Recursion Pharmaceuticals
(
Get Free Report)
Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company's proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.
At the core of Recursion's offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
